Annual report [Section 13 and 15(d), not S-K Item 405]

Document And Entity Information

v3.25.1
Document And Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 14, 2025
Jun. 24, 2024
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Transition Report false    
Entity File Number 001-36291    
Entity Registrant Name DIAMEDICA THERAPEUTICS INC.    
Entity Incorporation, State or Country Code A1    
Entity Address, Address Line One 301 Carlson Parkway, Suite 210    
Entity Address, City or Town Minneapolis    
Entity Address, State or Province MN    
Entity Address, Postal Zip Code 55305    
City Area Code 763    
Local Phone Number 496-5454    
Title of 12(b) Security Voting Common Shares, no par value per share    
Trading Symbol DMAC    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 71
Entity Common Stock, Shares Outstanding (in shares)   42,855,660  
Auditor Firm ID 23    
Auditor Name Baker Tilly US, LLP    
Auditor Location Minneapolis, Minnesota    
Entity Central Index Key 0001401040    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag false